These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 15381054)

  • 1. Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
    Serebruany VL; Malinin AI; Sane DC; Jilma B; Takserman A; Atar D; Hennekens CH
    Eur J Pharmacol; 2004 Sep; 499(3):315-24. PubMed ID: 15381054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
    Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
    Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage?
    Serebruany VL; Malinin AI; Sane DC
    Am J Hematol; 2003 Apr; 72(4):280-1. PubMed ID: 12666142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan).
    Serebruany VL; Malinin AI; Hanley DF
    Thromb Haemost; 2008 Jan; 99(1):116-20. PubMed ID: 18217142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy.
    Serebruany V; Sani Y; Eisert C; Schevchuck A; Fong A; Hanley D
    Thromb Haemost; 2011 Jan; 105(1):81-7. PubMed ID: 20978715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
    Serebruany VL; Malinin AI; Pokov A; Barsness G; Hanley DF
    Am Heart J; 2008 Jan; 155(1):93.e1-7. PubMed ID: 18082496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease.
    Serebruany VL; Malinin AI; Atar D; Hanley DF
    Am Heart J; 2007 Mar; 153(3):371-7. PubMed ID: 17307414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
    Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
    Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
    Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
    Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness.
    Serebruany V; Malinin A; Ziai W; Atar D; Pokov A; Jilma B; Hanley D
    Cerebrovasc Dis; 2006; 21(1-2):98-105. PubMed ID: 16340184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial change in platelet activation markers with aspirin and clopidogrel after acute ischemic stroke.
    Tsai NW; Chang WN; Shaw CF; Jan CR; Chang HW; Huang CR; Chen SD; Chuang YC; Lee LH; Lu CH
    Clin Neuropharmacol; 2010; 33(1):40-5. PubMed ID: 19855266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
    Tobin WO; Kinsella JA; Collins DR; Coughlan T; O'Neill D; Egan B; Tierney S; Feeley TM; Murphy RP; McCabe DJ
    Br J Haematol; 2011 Mar; 152(5):640-7. PubMed ID: 21223254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
    Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.
    Serebruany VL; Malinin AI; Ziai W; Pokov AN; Bhatt DL; Alberts MJ; Hanley DF
    Stroke; 2005 Oct; 36(10):2289-92. PubMed ID: 16151033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke.
    Cha JK; Jo WS; Shin HC; Bae HR; Ho JM; Kim JW
    Platelets; 2004 Feb; 15(1):3-7. PubMed ID: 14985170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
    Serebruany VL; Malinin AI; Atar D
    Cardiology; 2007; 107(4):307-12. PubMed ID: 17264511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.